六味五灵片联合胸腺五肽治疗肝纤维化临床疗效观察

目的探讨六味五灵片联合胸腺五肽治疗慢性乙型肝炎后肝纤维化的临床疗效。方法将72例慢性乙型肝炎后肝纤维化患者随机分为治疗组38例和对照组34例。治疗组给予六味五灵片联合胸腺五肽进行治疗,对照组仅给予胸腺五肽,疗程均为12周,治疗结束后随访12周。比较两组患者肝功能、肝纤维化四项指标、无创瞬间肝纤维化检测情况。结果治疗及随访结束后,治疗组ALT复常率与对照组比较,差异有显著统计学意义（P〈0.01）。治疗组治疗后血清肝纤维化指标均明显改善,与对照组比较,差异有统计学意义（P〈0.05）。两组治疗后无创瞬间肝纤维化检测数值均明显降低。结论六味五灵片联合胸腺五肽治疗慢性乙型肝炎后肝纤维化,可以改善受损肝脏功能,减轻肝脏内炎性反应,延缓肝纤维化进展。

Clinical effect of combination of Liuweiwuling tablets and thymopentin on liver fi brosis

Objective To explore the clinical effect of Liuweiwuling tablets and thymopentin for chronic hepatitis B cases with liver fibrosis. Methods Total of 72 chronic hepatitis B cases with liver fibrosis were randomly divided into control group （34 cases） and treatment group （38 cases）. Treatment group were treated with Liuweiwuling tablets combined with thymopentin. Control group were treated with thymopentin only. The course of treatment were 12 weeks, as well as the course of following-up visit. Liver functions, liver fibrosis indexes and liver fibrosis noninvasive value of both groups were measured after therapy and the results of the two groups were compared. Results Liver function recovery rate and serum liver fibrosis indexes were significantly improved in both groups, compared with before treatment （all P 0.05）. And there were significant differences between the two groups after treatment （P 0.05）. Liver fibrosis noninvasive value of both groups decreased significantly after treatment. Conclusions Liuweiwuling tablets combined with thymopentin is effective and safe in the treatment of liver fibrosis after chronic hepatitis B. It can improve liver function and inhibit the progress of liver fibrosis.